Updates are available Correction dated 2023-10-09

Article History

Received: 14 June 2023

Accepted: 3 August 2023

First Online: 17 August 2023

Change Date: 9 October 2023

Change Type: Correction

Change Details: A Correction to this paper has been published:

Change Details: https://doi.org/10.1007/s40618-023-02208-y

Declarations

:

: The authors declare the following competing financial interests: Dr Pedersini received consultancy fees from Roche, Novartis, Eli Lilly, Daiichi Sankyo, Gilead, Eisai, Accord, outside the submitted work; Dr. Torrisi received research grants from Pfizer, consultancy fees from MSD and lecture fees from Pfizer, Eli Lilly, EISAI and Genomic Health outside the submitted work; Dr. Vena received grants from IBSA Pharmaceutical outside the submitted work; Dr. Zambelli received consultancy fees from Roche, Novartis, Pfizer, Eli Lilly & Co., AstraZeneca, Genomic Health outside the submitted work; Dr. Bossi received research grants from Novo-Nordisk, Eli Lilly, Bayer, Sanofi Italia and advisory board and consultancy fees from MSD, Alfasigma, Boehringer Ingelheim, Astra Zeneca, Mundipharma Italia, Pfizer outside the submitted work; Dr. Lania received grants from Pfizer and consultancy fees from Ipsen, outside the submitted work; Dr. Berruti reports receiving grants and personal fees from Janssen Cilag, grants and personal fees from Astellas, and personal fees from Bayer outside the submitted work; Dr. Mazziotti received consultancy fees from Novartis, Ipsen, Eli Lilly and lecture fees from Amgen and Abiogen, outside the submitted work.

: The study was approved by the Ethics Committee of IRCCS Humanitas Research Hospital.

: The study was conducted in accordance with the Declaration of Helsinki, and all participants gave their written informed consent.

: No Informed Consent.